SubsidieMeestersPre-clinical validation and demonstration of PeptiCHIP: an immunopurification microfluidic device and software for (neo)antigen identification and prioritization
Valo Therapeutics is developing PeptiCHIP, a microfluidic device and algorithm to efficiently identify neoantigens for personalized cancer immunotherapy, enhancing patient response rates.
Projectdetails
Introduction
Clinical translation of cancer immunotherapies remains very challenging since 60-80% of patients fail to respond. The challenge stands in identifying specific tumour-fingerprints – the neoantigens - that are peptides expressed uniquely by cancer cells and that are capable of triggering an efficient immune response against cancer.
Current Limitations
Currently, there is no standard method to identify antigens, and the few methods available have significant limitations by being quite long, complicated, and resource-demanding.
PeptiCHIP Introduction
In response to this clear technological and market gap, Valo Therapeutics (ValoTx, an immunotherapy development company) is introducing PeptiCHIP, i.e., an innovative microfluidic immunopurification device and a peptide prioritization algorithm to identify the most relevant (neo)antigens to stimulate the immune system and thus increase the chance of success of the immunotherapy.
Adaptability and Proof of Concept
PeptiCHIP can be adapted and used to identify antigens related to any disease. The Proof of Concept (PoC) was successfully demonstrated at the University of Helsinki. The IP was protected, and ValoTx has full rights to further develop, exploit, and commercialize PeptiCHIP.
Project Goals
This EIC Transition project will allow further technology development, testing, validating, and demonstrating it pre-clinically, generating evidence to convince investors and stakeholders, as well as to prepare an extensive and solid transition-to-market plan (T2MP).
Impact Areas
By being accurate, fast, low-cost, easy to use, and working with very small amounts of samples, PeptiCHIP will have a great impact in:
- Research: For discovery & new therapies development since identification of antigens allows the understanding of diseases & immune response mechanisms.
- Industry: For therapy development & translation into clinical use since the antigens identification & prioritization is a critical step to produce therapies tailored for each patient to ensure responsiveness.
- Clinic: For patient assessment & immunotherapy tailoring.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.226.280 |
| Totale projectbegroting | € 2.226.280 |
Tijdlijn
| Startdatum | 1-4-2023 |
| Einddatum | 30-9-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- VALO THERAPEUTICS OYpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Very High Energy Electrons Beam for RadiotherapyeBeam4Therapy aims to revolutionize cancer treatment by developing compact, cost-effective VHEE radiotherapy using laser plasma accelerators to improve patient outcomes and reduce side effects. | EIC Transition | € 2.477.043 | 2022 | Details |
High-throughput hyperspectral imaging across the VIS-SWIR spectrum in a single deviceThe HYPERIA project aims to develop a novel hyperspectral imaging camera using Fourier Transform interferometry for enhanced sensitivity and wavelength range, targeting applications in food safety and waste separation. | EIC Transition | € 1.500.000 | 2022 | Details |
Therapeutic Antisense Oligonucleotides Targeting NUMB Alternative Splicing in Lung AdenocarcinomaThis project aims to develop Antisense Oligonucleotides to correct pathological splicing of the NUMB gene in lung adenocarcinomas, improving treatment efficacy and paving the way for clinical trials. | EIC Transition | € 2.899.553 | 2022 | Details |
Photonic chip based high-throughput, multi-modal and scalable optical nanoscopy platformNanoVision aims to revolutionize optical nanoscopy with an affordable, compact, and high-throughput photonic-chip solution, enhancing accessibility and flexibility for research and clinical labs. | EIC Transition | € 2.489.571 | 2022 | Details |
Very High Energy Electrons Beam for Radiotherapy
eBeam4Therapy aims to revolutionize cancer treatment by developing compact, cost-effective VHEE radiotherapy using laser plasma accelerators to improve patient outcomes and reduce side effects.
High-throughput hyperspectral imaging across the VIS-SWIR spectrum in a single device
The HYPERIA project aims to develop a novel hyperspectral imaging camera using Fourier Transform interferometry for enhanced sensitivity and wavelength range, targeting applications in food safety and waste separation.
Therapeutic Antisense Oligonucleotides Targeting NUMB Alternative Splicing in Lung Adenocarcinoma
This project aims to develop Antisense Oligonucleotides to correct pathological splicing of the NUMB gene in lung adenocarcinomas, improving treatment efficacy and paving the way for clinical trials.
Photonic chip based high-throughput, multi-modal and scalable optical nanoscopy platform
NanoVision aims to revolutionize optical nanoscopy with an affordable, compact, and high-throughput photonic-chip solution, enhancing accessibility and flexibility for research and clinical labs.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Nano-assisted digitalizing of cancer phenotyping for immunotherapyThe ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes. | ERC COG | € 1.993.875 | 2023 | Details |
Neoantigen Identification with Dendritic Cell ReprogrammingThe NeoIDC project aims to revolutionize cancer immunotherapy by using cDC1 reprogramming to identify immunogenic neoantigens and TCRs for developing effective vaccines and adoptive T cell therapies. | ERC POC | € 150.000 | 2023 | Details |
Fast and simple biomarker detection by computational microscopyWe developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics. | ERC POC | € 150.000 | 2024 | Details |
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors. | EIC Accelerator | € 2.496.112 | 2024 | Details |
Nano-assisted digitalizing of cancer phenotyping for immunotherapy
The ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes.
Neoantigen Identification with Dendritic Cell Reprogramming
The NeoIDC project aims to revolutionize cancer immunotherapy by using cDC1 reprogramming to identify immunogenic neoantigens and TCRs for developing effective vaccines and adoptive T cell therapies.
Fast and simple biomarker detection by computational microscopy
We developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics.
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.
The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors.